IDEXX Laboratories, Inc. $IDXX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 173,327 shares of the company’s stock after purchasing an additional 23,029 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.22% of IDEXX Laboratories worth $92,962,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in IDXX. Opal Wealth Advisors LLC acquired a new position in IDEXX Laboratories during the 2nd quarter valued at about $29,000. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories during the 2nd quarter valued at $36,000. NewSquare Capital LLC increased its position in shares of IDEXX Laboratories by 87.5% during the 2nd quarter. NewSquare Capital LLC now owns 75 shares of the company’s stock valued at $40,000 after purchasing an additional 35 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after buying an additional 30 shares during the period. Finally, WPG Advisers LLC acquired a new position in IDEXX Laboratories during the first quarter worth about $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. BTIG Research lifted their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. UBS Group upped their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Piper Sandler restated a “neutral” rating and set a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Sunday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $730.50.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director owned 262 shares in the company, valued at $169,600.46. This represents a 89.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Down 1.1%

Shares of IDXX traded down $7.27 during trading hours on Monday, hitting $682.66. 35,444 shares of the company were exchanged, compared to its average volume of 648,642. The firm’s 50 day moving average is $651.74 and its 200-day moving average is $589.87. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $735.00. The company has a market cap of $54.51 billion, a PE ratio of 57.05, a PEG ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the company posted $2.80 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.